Verici Dx (Verici Dx) EBIT per Share : $-0.07 (TTM As of Jun. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Verici Dx EBIT per Share?

Verici Dx's EBIT per Share for the six months ended in Jun. 2023 was $-0.03. Its EBIT per Share for the trailing twelve months (TTM) ended in Jun. 2023 was $-0.07.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for Verici Dx's EBIT per Share or its related term are showing as below:

VRCDF's 3-Year EBIT Growth Rate is not ranked ^*
in the Medical Diagnostics & Research industry.
Industry Median: -1.7
* Ranked among companies with meaningful 3-Year EBIT Growth Rate only.

Verici Dx's EBIT for the six months ended in Jun. 2023 was $-5.26 Mil.

Verici Dx EBIT per Share Historical Data

The historical data trend for Verici Dx's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Verici Dx EBIT per Share Chart

Verici Dx Annual Data

Trend

Dec20

Dec21

Dec22

EBIT per Share

-0.06

-0.07

Verici Dx Semi-Annual Data
	Jun21	Dec21	Jun22	Dec22	Jun23
EBIT per Share	-0.02	-0.04	-0.03	-0.04	-0.03

Verici Dx EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

Verici Dx's EBIT per Share for the fiscal year that ended in Dec. 2022 is calculated as

	EBIT per Share		(A: Dec. 2022 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-11.402	/	164.668
=	-0.07

Verici Dx's EBIT per Share for the quarter that ended in Jun. 2023 is calculated as

	EBIT per Share		(Q: Jun. 2023 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-5.258	/	170.319
=	-0.03

EBIT per Share for the trailing twelve months (TTM) ended in Jun. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was $-0.07

Verici Dx (OTCPK:VRCDF) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

Verici Dx EBIT per Share Related Terms

Thank you for viewing the detailed overview of Verici Dx's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Verici Dx (Verici Dx) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Verici Dx PLC (OTCPK:VRCDF) » Definitions » EBIT per Share

Comparable Companies

Traded in Other Exchanges

VRCI:UK

Address

19 Stanwell Road, Avon House, Penarth, Cardiff, GBR, CF64 2EZ

Website

https://www.vericidx.com

Verici Dx PLC is an immuno-diagnostics development company. The company is focused on developing diagnostics technologies which will help understand the outcomes of an organ transplant surgery. There are two products for clinical validation and commercialization: Clarava, which is a pre-transplant prognosis for the risk of early acute rejection; and Tuteva, a post-transplant diagnostic focused upon acute cellular rejection including sub-clinical rejection not being diagnosed through the current standard of care of rising serum creatine levels. The business of the Group comprises a single activity, that of the development of prognostic and diagnostic tests for kidney transplant patients.

Verici Dx (Verici Dx) Headlines

No Headlines